United Therapeutics | UTHR - Debt


United Therapeutics reported $200M in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
Amarin USD 0 0 Mar/2025
Ardelyx USD 208.26M 653K Mar/2026
Baxter International USD 9.69B 93M Mar/2026
Bayer EUR 36.45B 2.93B Dec/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Biogen USD 7.69B 398.3M Sep/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Emergent BioSolutions USD 903.2M 495.2M Jun/2023
Gilead Sciences USD 26.25B 4.07B Jun/2026
GlaxoSmithKline GBP 18.24B 818M Jun/2026
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Insmed USD 725.8M 1.82M Jun/2026
Ionis Pharmaceuticals USD 1.91B 425.5M Jun/2026
J&J USD 49.04B 5.95B Jun/2026
Lexicon Pharmaceuticals USD 99.51M 243K Dec/2023
Moderna USD 1.3B 7M Mar/2026
Omeros USD 442.16M 199K Sep/2023
Pfizer USD 63.19B 536M Jun/2026
PTC Therapeutics USD 696.47M 409.53M Jun/2026
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Sangamo BioSciences USD 0 0 Jun/2022
Sarepta Therapeutics USD 1.04B 3.08M Mar/2026
Teva Pharmaceutical Industries USD 16.91B 187M Mar/2026
United Therapeutics USD 200M 100M Mar/2025
Vertex Pharmaceuticals USD 1.98B 8.9M Jun/2026